These comprehensive findings establish that cardiac-specific STING inhibition not only ameliorates diabetes-induced electro-physiological remodeling but also mitigates structural changes including atrial dilation and fibrosis, highlighting STING as a promising therapeutic target for diabetic-related AF. This evidence concerns the gene STING1 and atrial fibrillation.